Papillary thyroid carcinoma is a malignant epithelial neoplasm derived from the thyroid follicular epithelium, defined by specific nuclear features and by a generally indolent but highly variable biological behavior. Its name should not cause confusion with follicular carcinoma: both belong to the malignant tumors derived from thyroid follicular cells, but papillary carcinoma is recognized primarily by its nuclear alterations, its frequent dependence on the MAPK pathway and its preferential tendency toward cervical lymphatic spread. Papillary growth may be present, but it is not essential in every variant, because the histological diagnosis is based on the combined assessment of architecture, nuclear cytology, invasiveness and correlation with the updated pathological classification.
It is the most common malignant tumor of the thyroid and accounts for the vast majority of differentiated thyroid carcinomas. The increase in incidence observed over recent decades is largely attributable to the greater ultrasonographic detection of small nodules and microcarcinomas, while mortality has remained relatively low compared with the frequency of diagnosis. Its epidemiological profile is characterized by a predominance in females, a broad age distribution and a higher incidence in adults, although it may also occur in children, in whom multifocality, lymph node involvement and pulmonary metastases are more frequent, while the prognosis remains favorable in most cases. The main clinical issue is not merely to recognize the presence of the tumor, but to distinguish low-risk carcinoma, which can often be cured with conservative treatment, from biologically aggressive, recurrent, invasive or radioactive iodine-refractory carcinoma.
Papillary carcinoma arises from transformed thyroid follicular cells, namely the epithelial cells that normally participate in thyroid hormone synthesis. This cellular origin, which is shared by differentiated carcinomas, does not mean that papillary carcinoma and follicular carcinoma are the same disease. In papillary carcinoma, neoplastic transformation produces a characteristic nuclear phenotype, often associated with molecular drivers that predominantly activate the mitogen-activated protein kinase (MAPK) pathway, whereas true follicular carcinoma more typically follows an encapsulated or infiltrative growth pattern in which capsular and vascular invasion are central diagnostic features. In papillary carcinoma, by contrast, nuclear morphology often allows a presumptive cytological diagnosis to be made on fine-needle aspiration.
Papillary carcinoma cells show enlarged, oval or elongated, optically clear nuclei with overlapping, nuclear membrane irregularities, longitudinal grooves, intranuclear pseudoinclusions and altered chromatin distribution. Psammoma bodies, when present, are laminated calcifications that are often associated with degenerated papillae or intraglandular lymphatic spread. The presence of true papillae, composed of a fibrovascular core lined by neoplastic cells, supports the diagnosis, but some variants are predominantly follicular, solid, trabecular, diffuse sclerosing or characterized by rarer architectural patterns. The modern concept of papillary carcinoma therefore focuses on its nuclear features and overall histological category, rather than on the mere presence of papillary structures.
The 2022 World Health Organization (WHO) classification consolidated an integrated view of thyroid tumors derived from follicular cells by combining morphology, invasiveness, molecular profile and clinical behavior. Papillary carcinoma includes classic forms and variants with different prognostic implications: classic papillary carcinoma, infiltrative follicular variant, tall-cell variant, columnar-cell variant, hobnail variant, diffuse sclerosing variant, solid or trabecular variant and other less common forms. Papillary microcarcinoma, defined by a maximum diameter of 1 cm, is not a distinct biological entity. It may be an indolent finding, may be multifocal or may occasionally be associated with metastatic lymph nodes, and its significance depends on its location, contact with the capsule, relationship with the trachea or recurrent laryngeal nerve, ultrasonographic profile and the presence of lymph node metastases.
The follicular variant requires particular precision because it may create terminological overlap with follicular carcinoma. The follicular variant of papillary carcinoma has a follicular architecture but nuclei characteristic of papillary carcinoma. It may be infiltrative, encapsulated and invasive, or, when strictly noninvasive and meeting the appropriate morphological criteria, it may fall within the category of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). NIFTP should not be treated as invasive papillary carcinoma, because the category was introduced specifically to prevent overdiagnosis and overtreatment of biologically very indolent encapsulated follicular lesions. The distinction is histological, requires complete assessment of the capsule and cannot be established with certainty by cytology alone, because the absence of capsular invasion and vascular invasion must be demonstrated in the surgical specimen.
Aggressive variants have a clinical impact that is disproportionate to their frequency. The tall-cell variant is often associated with older age, the B-Raf proto-oncogene (BRAF) p.V600E mutation, greater extrathyroidal extension and recurrence. The hobnail variant, particularly when the characteristic component is extensive, shows loss of cell polarity, micropapillary growth and a greater likelihood of invasion, metastasis and an unfavorable clinical course. The diffuse sclerosing variant often affects young patients, may diffusely involve one or both lobes and is characterized by fibrosis, lymphocytic infiltration, squamous metaplasia, numerous psammoma bodies and frequent lymph node or pulmonary metastases. The solid variant, which is more common in pediatric patients and post-radiation tumors, and the columnar-cell variant also require particular attention because they may behave more aggressively. The presence of a high-risk histological variant modifies prognostic stratification and may influence the extent of surgery, the indication for radioactive iodine and the intensity of follow-up.
Papillary carcinoma may show oncocytic areas without being equivalent to oncocytic thyroid carcinoma. Oncocytic change describes cells rich in mitochondria, with abundant granular eosinophilic cytoplasm, and may occur in benign, inflammatory or neoplastic settings. When a tumor retains the architecture and nuclei of papillary carcinoma, it remains a papillary carcinoma with oncocytic features. When the neoplasm is instead a primary oncocytic carcinoma, diagnostic and prognostic assessment follows its own criteria, based on capsular or vascular invasion, hematogenous behavior and distinct biology. This distinction prevents the inappropriate application to papillary carcinoma of concepts that belong to oncocytic carcinoma and safeguards the accuracy of the histopathological diagnosis.
The only clearly established environmental cause of papillary carcinoma is exposure to ionizing radiation, particularly when it occurs during childhood. Therapeutic irradiation of the neck, nuclear accidents and internal exposure to radioactive iodine isotopes increase the risk through DNA damage, double-strand breaks and chromosomal rearrangements. The risk is greater in growing thyroid tissue because cell proliferation increases the likelihood that a genetic lesion will become fixed within a clone. Following radiation exposure, papillary carcinoma more frequently shows rearrangements involving rearranged during transfection (RET) and neurotrophic tyrosine receptor kinase (NTRK), resulting in constitutive activation of receptor tyrosine kinases or fusion kinases that converge on the MAPK pathway.
Risk factors are not equivalent to established causes, but they increase the probability of diagnosis or influence the biological context. Female sex, a family history of nonmedullary thyroid carcinoma, certain hereditary syndromes, age, obesity, medical or environmental radiation exposure and greater ultrasonographic surveillance contribute to the observed disease burden to varying degrees. A proportion of familial nonmedullary tumors do not fall within defined monogenic syndromes, whereas certain syndromic conditions, such as familial adenomatous polyposis caused by alterations in adenomatous polyposis coli (APC), PTEN hamartoma tumor syndrome caused by alterations in phosphatase and tensin homolog (PTEN), disorders associated with DICER1 ribonuclease III (DICER1) and other rare predisposition syndromes, may include thyroid tumors within their spectrum. A family history should therefore be interpreted as a clinical signal, not as automatic evidence of simple inheritance.
Chronic autoimmune thyroiditis is frequently associated with nodules and with the detection of papillary carcinoma in surgical specimens, but the causal relationship remains complex. Lymphocytic infiltration may facilitate ultrasonographic diagnosis, increase the frequency of surveillance and produce a microenvironment rich in cytokines, oxidative stress and repair signals. However, an epidemiological association does not automatically demonstrate that autoimmunity causes the tumor, nor does it justify considering every case of thyroiditis to be a precancerous condition. The correct clinical approach is more cautious: thyroiditis may obscure or mimic suspicious nodules, may alter the echogenicity and palpability of the gland and requires ultrasonography performed with particular attention to the cervical lymph nodes and signs of suspicious focal lesions.
The most common molecular mechanism in adult papillary carcinoma is activation of the MAPK pathway. The BRAF p.V600E mutation produces constitutive activation of the BRAF kinase independently of upstream receptor signals and stimulates the rapidly accelerated fibrosarcoma (RAF), mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) cascade. The result is increased proliferation, cell survival, motility, remodeling of the microenvironment and reduced expression of thyroid-specific genes. This loss of differentiation may reduce iodine uptake through the sodium iodide symporter (NIS), namely the sodium-iodide transporter, making some advanced tumors less responsive to radioactive iodine.
RET/PTC rearrangements and NTRK fusions produce chimeric proteins with permanent tyrosine kinase activity. Because RET is not normally expressed in adult thyroid follicular cells, its ectopic activation through fusion with partner genes creates an abnormal proliferative signal. NTRK fusions act in a similar manner, generating active kinases that support MAPK signaling and, in some settings, phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) signaling. Fusions are more common than the BRAF p.V600E mutation in children and in radiation-associated carcinomas. This distinction is clinically relevant because RET and NTRK fusions are also therapeutic targets in advanced, metastatic or conventionally treatment-refractory disease.
Papillary carcinoma does not always progress through a single alteration. Aggressive tumors may acquire mutations in the promoter of telomerase reverse transcriptase (TERT), alterations in tumor protein p53 (TP53), events involving PI3K/AKT, loss of differentiation and increasing genomic instability. The coexistence of BRAF p.V600E and TERT promoter mutations is particularly unfavorable because it combines MAPK-dependent proliferation, replicative immortality and reduction of the differentiated thyroid program. This explains why two papillary carcinomas of the same size may follow different clinical trajectories: diameter is important, but behavior results from the integration of location, invasion, histological type, lymph node status, mutations, response to iodine and differentiation status.
Progression to poorly differentiated or anaplastic disease is rare, but represents the extreme end of the biological continuum. During this process, the tumor loses follicular features, reduces or abolishes its ability to take up iodine, accumulates additional genetic alterations, increases its proliferative rate and acquires local or metastatic invasiveness. Classic low-risk papillary carcinoma often remains confined to the thyroid or regional lymph nodes, whereas dedifferentiated tumors develop greater treatment resistance. Dedifferentiation is therefore not a generic morphological label, but the functional consequence of molecular remodeling that reduces dependence on the normal thyroid program.
Papillary carcinoma may grow within the thyroid parenchyma as a solitary nodule, a multifocal lesion or a more diffuse process, depending on the variant. Multifocality is common and may reflect intraglandular dissemination, a multicentric predisposition or the detection of independent microscopic foci. Bilaterality does not automatically imply highly aggressive disease, but it influences surgical planning and follow-up because residual contralateral thyroid tissue may complicate the interpretation of thyroglobulin and ultrasonographic surveillance. The assessment of multifocality must therefore be incorporated into an overall evaluation that also considers the size of the main focus, capsular location, margins, lymph nodes and histological type.
Lymphatic spread is the feature that most clearly distinguishes papillary carcinoma from follicular carcinoma. Tumor cells may enter intrathyroidal lymphatic vessels and first reach the central compartment of the neck, namely levels VI and VII, and subsequently the lateral compartments, particularly levels III, IV and V. Metastatic lymph nodes may be solid, cystic, calcified or hypervascular and may occasionally represent the first clinical sign of disease, even when the primary tumor is small. The presence of metastatic lymph nodes increases the risk of locoregional recurrence, but its impact on survival depends on age, nodal burden, number of involved lymph nodes, size of the metastases, extranodal extension and association with other factors affecting structural risk.
Extrathyroidal extension must be distinguished as microscopic or macroscopic. Minimal histological extension beyond the thyroid capsule, detectable only microscopically, has lost part of its importance in modern prognostic staging, whereas macroscopic invasion of the strap muscles, trachea, larynx, esophagus, recurrent laryngeal nerve, subcutaneous soft tissues, prevertebral fascia or major vessels radically changes its clinical significance. Recurrent laryngeal nerve invasion may cause dysphonia and vocal cord paralysis. Tracheal invasion may produce cough, hemoptysis, dyspnea or stenosis, while esophageal involvement may cause dysphagia. Macroscopic invasion is therefore a much more important prognostic and therapeutic factor than simple adherence or minimal microscopic extension.
Distant metastases are less common than lymph node metastases, but they alter the prognosis. The lung is the most typical site, particularly in children and young patients, in whom metastases may present as diffuse, radioiodine-avid micronodules. Bone involvement is less frequent but more clinically burdensome because it may cause pain, pathological fractures, spinal cord compression and a lower probability of complete response to radioactive iodine. More rarely, the brain, liver, skin or other sites may be involved. The significance of metastases depends on tumor burden, rate of progression, iodine uptake, symptoms and the presence of refractory disease.
Papillary carcinoma may remain clinically silent for years. Some microcarcinomas do not grow or grow very slowly, whereas others show early lymph node progression. The difference cannot be explained by a single parameter, but by a combination of tumor biology, age, local immunity, anatomical location and molecular drivers. A small tumor abutting the recurrent laryngeal nerve or trachea may be more clinically relevant than a slightly larger intraparenchymal nodule. A cystic lateral lymph node metastasis may provide more important information than the diameter of the primary tumor, and a hobnail or tall-cell variant requires greater attention even when the initial mass is not particularly large. Modern management is based on this integrated stratification, rather than on size alone.
The most common presentation is the incidental detection of a thyroid nodule during neck ultrasonography, imaging performed for other reasons or clinical examination. Patients are often euthyroid and report no specific symptoms because papillary carcinoma rarely produces thyroid hormones in clinically significant quantities. The medical history should establish the duration of the nodule, perceived growth, previous cervical radiation exposure, family history of thyroid tumors, hereditary syndromes, previous neck surgery, autoimmune thyroid disease, the development of lymphadenopathy, dysphonia, dysphagia, irritative cough, dyspnea, local pain and systemic symptoms. A normal thyroid-stimulating hormone (TSH) level does not exclude carcinoma because thyroid function and oncological risk are separate dimensions.
When the carcinoma is palpable, the patient may describe an anterior neck swelling that moves with swallowing and may be hard or irregular. Rapid growth is not typical of classic papillary carcinoma and should raise consideration of intranodular hemorrhage, thyroiditis, lymphoma, poorly differentiated carcinoma or anaplastic carcinoma, although it may also occur in aggressive papillary tumors or cystic lymph nodes. A lateral neck swelling, particularly if cystic, calcified or persistent, may represent a lymph node metastasis and should not automatically be mistaken for a lateral neck cyst. The most important historical finding is the relationship between local progression, compressive symptoms and the development of lymphadenopathy.
Physical examination follows the actual sequence of the clinical assessment. The neck is inspected at rest and during swallowing. The thyroid is palpated from the front or from behind to assess size, consistency, mobility, tenderness, margins and fixation to deeper planes, after which the central and lateral lymph node compartments are systematically examined. Palpation may be normal in the presence of small or deeply located tumors, whereas suspicious lymph nodes may be more apparent than the primary nodule. The voice, quality of phonation, signs of vocal cord paralysis, stridor, tracheal deviation, dysphagia, bone pain and respiratory symptoms should also be assessed. Dysphonia should not be generically attributed to anxiety or reflux because, in the context of a thyroid nodule, it may indicate involvement of the recurrent laryngeal nerve.
In children and adolescents, papillary carcinoma may present with lateral cervical lymph nodes, multifocality and, less commonly, micronodular pulmonary metastases. Despite the often greater anatomical extent compared with adults, survival is generally high because many pediatric tumors retain differentiation and iodine uptake. In older patients, by contrast, a locally invasive mass, an aggressive variant or a mutation associated with dedifferentiation has a greater prognostic impact. Age therefore modifies the significance of the same finding: a cervical lymph node metastasis in a young patient may coexist with long survival, whereas an invasive tumor in an older adult requires a more intensive and multidisciplinary assessment.
Distant metastatic disease may be asymptomatic and detected by imaging or post-treatment scintigraphy, or it may present with persistent cough, dyspnea, bone pain, fractures, neurological deficits or hypercalcemia caused by extensive bone lesions. These presentations are uncommon, but they should be investigated in patients with large tumors, aggressive variants, elevated thyroglobulin after treatment, multiple lymph nodes or refractory disease. The absence of symptoms does not justify minimizing the risk when anatomical and biological findings indicate advanced disease. Clinical assessment must always connect the tumor phenotype, anatomical extent and likelihood of persistence or recurrence.
The diagnostic pathway begins when a thyroid nodule or cervical lymph node shows suspicious clinical or ultrasonographic features. Initial assessment includes medical history, physical examination, measurement of thyroid-stimulating hormone (TSH) and high-resolution ultrasonography of the thyroid and neck. TSH defines the functional context: when it is suppressed, thyroid scintigraphy may identify an autonomously functioning hyperactive nodule, which has a lower probability of malignancy than a nonfunctioning nodule, although the risk is not completely eliminated. Ultrasonography is the central examination because it describes composition, echogenicity, margins, shape, echogenic foci, capsule, relationships with adjacent structures and suspicious lymph nodes.
The ultrasonographic features most suggestive of papillary carcinoma include a solid hypoechoic nodule, irregular or infiltrative margins, a taller-than-wide shape, microcalcifications, extrathyroidal extension, capsular disruption and lymphadenopathy with loss of the fatty hilum, microcalcifications, cystic components, hyperechogenicity or abnormal peripheral vascularity. Systems such as the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) and the ultrasonographic patterns of the American Thyroid Association (ATA) help standardize risk assessment and determine when fine-needle aspiration (FNA) should be performed. The decision should not be based solely on diameter because a small nodule adherent to the trachea or located near the recurrent laryngeal nerve may require greater attention than an intraparenchymal nodule with a low-risk ultrasonographic pattern.
Ultrasound-guided fine-needle aspiration is the reference examination for the preoperative diagnosis of suspicious nodules. Cytology is reported according to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), which distinguishes nondiagnostic material, benign findings, atypia of undetermined significance, follicular neoplasm, suspicion for malignancy and malignancy. In classic papillary carcinoma, cytology may be strongly suggestive or diagnostic because of the presence of clear nuclei, grooves, pseudoinclusions and papillary architecture. In suspicious lymph nodes, fine-needle aspiration should be supplemented, when indicated, by measurement of thyroglobulin in the needle washout fluid, which is particularly useful in cystic or paucicellular lymph nodes. Confirmation of cytological malignancy guides surgery, but the definitive extent of the disease remains a histological determination.
The definitive diagnosis of the primary tumor is histopathological. The pathologist assesses size, histological type, variant, multifocality, margins, capsular invasion, vascular invasion, extrathyroidal extension, perineural infiltration, the number and location of examined lymph nodes, the size of metastases and the presence of extranodal extension. In tumors with a follicular growth pattern, the distinction between infiltrative follicular variant, encapsulated invasive lesions and NIFTP requires complete sampling of the capsule because cytology cannot demonstrate the absence of invasion. The diagnosis of papillary carcinoma should therefore not be reduced to a single term, but should include the information that defines biological risk, therapeutic strategy and follow-up.
According to the integrated approach of the ATA and European Society for Medical Oncology (ESMO) guidelines, establishing the diagnosis and correctly planning treatment require the correlation of clinical findings, ultrasonography, cytology, pathological anatomy and staging.
The practical sequence can be summarized only through its main decision points because each step modifies the pre-test probability and the subsequent choice:
Molecular tests do not replace pathological anatomy, but they have selected roles. In cytologically indeterminate nodules, they may help estimate the risk of malignancy and guide the choice between surveillance, lobectomy or more extensive surgery, depending on the clinical context and the availability of validated panels. In advanced, recurrent, metastatic or radioactive iodine-refractory carcinomas, molecular profiling should identify actionable alterations, including RET fusions, NTRK fusions, BRAF mutations, anaplastic alterations or markers of dedifferentiation. Molecular testing has its greatest value when it changes a specific decision regarding the extent of treatment, access to targeted therapies, clinical trials or prediction of radioiodine resistance.
Computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) are not first-line examinations for every papillary thyroid nodule, but they become important in bulky disease, suspected tracheal or esophageal invasion, retrosternal lymph nodes, complex recurrence, distant metastases or discordance between thyroglobulin and scintigraphy. Contrast-enhanced CT may be necessary to plan complex surgery, even though iodinated contrast temporarily interferes with subsequent radioactive iodine treatment. The priority is to define the anatomy accurately when the airways, nerves, vessels and mediastinum are involved. Advanced imaging should answer a specific question regarding anatomical extent, rather than merely increase the number of incidental findings.
The differential diagnosis includes benign nodules, follicular adenomas, multinodular goiter, chronic thyroiditis, noninvasive follicular lesions, NIFTP, follicular carcinoma, oncocytic carcinoma, medullary carcinoma, poorly differentiated carcinoma, thyroid lymphoma, intrathyroidal metastases and parathyroid lesions. In cystic lateral cervical lymph nodes, branchial cysts, metastases from oropharyngeal squamous cell carcinoma and metastases from occult papillary carcinoma must be considered. Calcitonin measurement, parathyroid hormone measurement in needle aspirates, immunohistochemistry and molecular markers may be required when morphology and location are not unequivocal. The essential objective is to avoid diagnosis based on superficial similarity and to achieve a definition grounded in targeted cytology, histology and the clinical context.
In papillary thyroid carcinoma, staging must be interpreted on two different levels because it answers two distinct clinical questions. The eighth edition of the American Joint Committee on Cancer (AJCC) system, based on tumor-node-metastasis (TNM), is primarily intended to estimate the risk of disease-specific death from differentiated thyroid carcinoma. The American Thyroid Association (ATA) classification, by contrast, estimates the risk of persistent or recurrent structural disease after initial treatment. This distinction is essential: a young patient with cervical lymph node metastases may have a low AJCC stage in terms of survival, but not a low ATA risk of locoregional recurrence.
The first component of staging describes the anatomical extent of the primary tumor. The T category does not correspond simply to diameter because, in more advanced tumors, macroscopic invasion of the perithyroidal tissues is of major importance. In papillary carcinoma, isolated microscopic extrathyroidal extension has less prognostic weight than in previous editions, whereas macroscopic invasion of muscles, airways, esophagus, recurrent laryngeal nerve or vascular structures substantially modifies prognosis and treatment.
local extent - T
The second component concerns the regional lymph nodes. Lymphatic spread is frequent in papillary carcinoma and first involves the central compartment, followed by the lateral compartments of the neck. Lymph node metastases mainly increase the risk of persistent or recurrent cervical disease. Their impact on mortality depends on age, metastatic burden, number of involved lymph nodes, size of the metastases, extranodal extension and the coexistence of other unfavorable factors. The N category should therefore indicate not only whether lymph nodes are positive, but also where they are located.
lymph node involvement - N
The third component of the TNM classification concerns distant metastases. In papillary carcinoma, the most clinically relevant sites are the lungs and bones, whereas involvement of the brain, liver, skin and other organs is less common. The presence of metastases does not have the same significance in every patient. Radioiodine-avid pulmonary micronodules in a young patient may follow a prolonged course and respond well to radioactive iodine, whereas bone metastases, non-radioiodine-avid lesions or progressive disease indicate a less favorable profile. The M category must therefore be explicitly reported.
metastatic spread - M
After T, N and M have been established, the AJCC stage is assigned differently according to age, using 55 years as the threshold. In patients younger than 55 years, the system is intentionally simple because disease-specific survival is very high even in the presence of regional lymph nodes. This does not mean that lymph nodes, local invasion or aggressive variants are irrelevant. It only means that they have less influence on the prediction of disease-specific mortality according to the AJCC system.
AJCC staging for patients younger than 55 years
In patients aged 55 years or older, AJCC staging is more detailed because tumor size, macroscopic invasion, lymph node involvement and distant metastases have a greater impact on disease-specific survival. In this age group, a small intrathyroidal tumor without lymph node involvement belongs to an early stage, whereas invasion of the aerodigestive structures, vascular encasement or distant metastases places the disease in an advanced stage. For patients aged at least 55 years, AJCC staging is as follows:
AJCC staging for patients aged at least 55 years
AJCC stage alone is not sufficient to determine the extent of surgery, the indication for radioactive iodine, the degree of thyroid-stimulating hormone (TSH) suppression or the frequency of follow-up. These decisions use the ATA recurrence-risk stratification system, which considers factors that are not fully represented by the numerical stage, including completeness of resection, histological variant, vascular invasion, extrathyroidal extension, lymph node burden, distant metastases, radioiodine uptake outside the thyroid bed and postoperative thyroglobulin. ATA stratification therefore translates the anatomical diagnosis into a practical estimate of persistence or recurrence.
ATA risk categories
Risk stratification does not end at the time of surgery. After surgery, any radioactive iodine treatment and the first follow-up assessments, the risk is recalculated according to the response to therapy. An excellent response markedly reduces the probability of recurrence and allows the intensity of surveillance and TSH suppression to be progressively reduced. An incomplete biochemical response requires interpretation of thyroglobulin and anti-thyroglobulin antibodies. An incomplete structural response indicates visible or confirmed disease and requires targeted treatment or selective surveillance according to location, growth and anatomical risk. Dynamic risk stratification therefore prevents patients from being managed for years solely according to their initial stage while ignoring the actual evolution of the disease.
Treatment must be proportionate to risk. In a patient with a unifocal, low-risk papillary microcarcinoma that is intrathyroidal, has no suspicious lymph nodes, no critical contact with the trachea or recurrent laryngeal nerve, no evidence of extrathyroidal extension and can reliably adhere to follow-up, active surveillance may be an appropriate option. This strategy involves serial ultrasonography, clinical assessment and delayed surgery only if significant growth, lymph node involvement or a change in anatomical risk occurs. Active surveillance is not therapeutic inertia. It is a structured management strategy intended to avoid unnecessary surgical complications in tumors with a very low probability of clinically relevant progression. Its rationale is to maximize the net benefit in patients with a genuinely low-risk microcarcinoma.
Surgery remains the cornerstone of treatment when the tumor is clinically significant, progressive, symptomatic, substantially multifocal, locally invasive, associated with lymph node disease or unsuitable for surveillance. Lobectomy may be sufficient for low-risk intrathyroidal tumors without clinically apparent lymph nodes and of a size compatible with conservative treatment, because it reduces the risk of permanent hypoparathyroidism and often avoids the need for complete replacement therapy or intensive TSH suppression. Total thyroidectomy is preferred for large or bilateral tumors, tumors with gross extrathyroidal extension, clinically significant lymph node metastases, distant metastases, an anticipated need for radioactive iodine or biochemical follow-up based on thyroglobulin. The choice between lobectomy and total thyroidectomy must reflect the actual risk rather than surgical habit.
Lymph node management requires anatomical precision. Therapeutic dissection of the central compartment is indicated when lymph nodes are clinically or cytologically metastatic. Lateral neck dissection should be compartment-oriented and therapeutic, rather than limited to removal of the most evident lymph node, when lateral metastasis has been documented. Prophylactic central compartment dissection is not routinely recommended for small, low-risk cN0 tumors because it increases the risk of hypoparathyroidism and recurrent laryngeal nerve injury without a proven benefit for every patient. It may be considered in advanced T3 or T4 tumors, in the presence of clinically apparent lateral lymph nodes or when nodal information would alter subsequent decisions. Lymph node surgery must balance locoregional control against morbidity.
Radioactive iodine with iodine-131 is not required in every papillary carcinoma. After total thyroidectomy, it may be used to ablate the remnant, provide adjuvant treatment for suspected microscopic disease or treat known radioiodine-avid disease. Indications are stronger in high-risk patients, patients with radioiodine-avid distant metastases, patients with incompletely resected disease that cannot be corrected surgically and selected intermediate-risk cases. It is generally unnecessary or highly selective in small, completely resected intrathyroidal tumors without unfavorable features. The decision must integrate size, histological type, extrathyroidal extension, lymph nodes, postoperative thyroglobulin, imaging, recurrence risk and the objectives of follow-up. Radioactive iodine treatment is effective only when the disease retains sufficient iodine avidity.
Levothyroxine therapy has two purposes: replacing lost thyroid function and modulating TSH, which may stimulate the growth and survival of differentiated thyroid cells. TSH suppression must be calibrated according to risk and response to therapy. More intensive suppression may be indicated in high-risk patients or those with persistent disease, whereas unnecessarily aggressive suppression should be avoided in low-risk patients with an excellent response. Chronic levothyroxine excess may promote atrial fibrillation, tachyarrhythmias, bone loss, worsening angina and reduced quality of life. Appropriate endocrine treatment does not aim for the same numerical target in every patient, but for a balance between oncological control and cardiovascular and skeletal safety.
External beam radiotherapy is not part of the standard treatment of resectable low-risk or intermediate-risk papillary carcinoma. It may have a role in locally advanced disease that cannot be completely resected, gross non-radioiodine-avid residual disease, aerodigestive invasion that cannot be controlled surgically or selected recurrences in patients for whom further surgery would carry high morbidity. Painful bone metastases or lesions at risk of fracture may require radiotherapy, orthopedic surgery, embolization, local ablation or systemic treatment, depending on their location and stability. The principle is to treat structural disease that creates an anatomical risk or causes symptoms, while avoiding nonspecific irradiation in patients who can be cured with surgery and follow-up.
Advanced disease that is refractory to radioactive iodine requires multidisciplinary evaluation. Refractoriness may be defined by lesions that do not take up iodine, loss of uptake after previous treatments, progression despite significant uptake or the achievement of cumulative doses beyond which the expected benefit is low. Not every refractory lesion requires immediate systemic treatment. Small, stable and asymptomatic lesions may be observed. When disease is progressive, symptomatic or threatens vital organs, antiangiogenic multikinase inhibitors such as lenvatinib and sorafenib have demonstrated a benefit in progression-free survival. In tumors with RET or NTRK fusions, selective agents such as selpercatinib, pralsetinib, larotrectinib or entrectinib may be considered according to regulatory approval, availability and molecular profile. The choice of systemic treatment must be based on documented progression, the molecular target and the anticipated toxicity.
The overall prognosis of papillary carcinoma is favorable, particularly for low-risk intrathyroidal tumors that are adequately treated or selected for active surveillance. Long-term disease-specific survival is very high in young patients without distant metastases, but locoregional recurrence is not uncommon in subgroups with large-volume lymph node disease, extranodal extension, macroscopic invasion, aggressive histology or a persistent biochemical response. Prognosis worsens with older age, distant metastases, dedifferentiation, radioiodine refractoriness, unfavorable co-mutations and inability to achieve local control. The correct clinical message is that papillary carcinoma is often curable, but not always trivial. The individual prognosis depends on the quality of staging and the proportionality of treatment.
Follow-up begins after initial treatment and must be adapted to the extent of surgery. After total thyroidectomy, serum thyroglobulin is the principal biochemical marker, provided that it is interpreted together with anti-thyroglobulin antibodies, the TSH level, the laboratory method and the presence or absence of residual thyroid tissue. Undetectable or very low thyroglobulin in the absence of antibodies, combined with negative ultrasonography, suggests an excellent response. Rising thyroglobulin requires investigation for structural disease even when the initial ultrasound is negative. After lobectomy, by contrast, thyroglobulin is less specific because normal thyroid tissue remains. The significance of the marker therefore depends on the surgical context.
Cervical ultrasonography is the most important imaging examination for locoregional follow-up. It should assess the thyroid bed, any residual tissue, the central compartment and the lateral compartments, distinguishing small scar-related findings from suspicious nodules and reactive lymph nodes from metastases. A suspicious lymph node should be investigated with fine-needle aspiration and thyroglobulin measurement in the needle washout fluid when confirmation would alter management. Excessively frequent ultrasonography in patients at very low risk who have achieved an excellent response may generate false alarms and unnecessary procedures. Conversely, follow-up intervals that are too long in patients with intermediate-risk or high-risk disease may delay recognition of an operable recurrence. The frequency of follow-up must reflect the dynamic response.
Whole-body radioactive iodine scintigraphy, CT, MRI and fluorodeoxyglucose positron emission tomography (FDG-PET) have selected indications. Scintigraphy is useful when assessing radioiodine-avid disease after treatment or in patients with intermediate-risk or high-risk disease. FDG-PET becomes more informative when thyroglobulin is elevated and radioiodine scintigraphy is negative because loss of iodine uptake is often associated with increased glucose metabolism. Chest CT detects pulmonary metastases, MRI is useful for the spine, brain and soft tissues, and targeted imaging helps plan surgery, radiotherapy or systemic treatment. The principle of advanced follow-up is to identify clinically relevant disease, rather than pursue every minor abnormality without therapeutic consequences.
Anti-thyroglobulin antibodies may mask or distort thyroglobulin levels because they interfere with many immunometric assays. In these cases, the antibody trend becomes an indirect indicator: a progressive decline is reassuring, whereas persistence or an increase may suggest residual or recurrent disease, particularly when associated with ultrasonographic abnormalities. Analytical variability between laboratories may also affect interpretation. For this reason, it is preferable to follow the patient using the same assay whenever possible. Biochemical data must be interpreted as a longitudinal trend, rather than as an isolated value.
Recurrence may occur in the neck, mediastinum or distant sites. Resectable lymph node recurrences may be treated with compartment-oriented surgery, avoiding fragmented procedures that increase fibrosis and neurological risk. Small, stable and nonthreatening lesions may be monitored, particularly when surgery would carry high morbidity and the disease burden is minimal. Radioiodine-avid metastases may benefit from radioactive iodine, whereas non-radioiodine-avid lesions require assessment of growth, symptoms, location and molecular profile. Appropriate follow-up does not mean immediately treating every finding, but intervening promptly when structural recurrence becomes clinically significant.
The complications of papillary carcinoma arise from the disease itself, its treatments and excessive follow-up. The most common oncological complications are persistent or recurrent locoregional disease, particularly in the lymph nodes. This occurs because the tumor may use the thyroid and cervical lymphatic network at an early stage, may be multifocal and may leave micrometastases that were not evident at the time of initial surgery. Lymph node recurrence may remain indolent, but it may require reoperation in a previously operated neck, increasing the risk of recurrent laryngeal nerve injury, hypoparathyroidism, lymphatic leakage and anatomical difficulty. Cervical recurrence is therefore both a biological and surgical complication.
Local invasion causes less frequent but more severe complications. Involvement of the recurrent laryngeal nerve may cause vocal cord paralysis, dysphonia, vocal fatigue and aspiration. Tracheal infiltration may result in hemoptysis, stenosis, dyspnea or the need for aerodigestive resections. Esophageal invasion may cause dysphagia and a risk of fistula during complex treatments. Locally advanced tumors require highly specialized surgery because inadequate resection increases persistent disease, whereas excessively extensive resection may cause permanent morbidity. The central complication is loss of control of the aerodigestive region.
Pulmonary metastases may remain clinically silent for years, particularly when they are micronodular and radioiodine-avid, but in extensive cases they may progress to respiratory deterioration, reduced diffusing capacity, cough or respiratory failure. Bone metastases have a greater clinical impact because they cause pain, pathological fractures, spinal cord compression, hypercalcemia and the need for repeated local treatments. Brain metastases are rare but serious because of the risk of neurological impairment, edema and bleeding. The severity of metastatic disease depends on its location, burden, growth and iodine sensitivity.
Radioactive iodine refractoriness is a biological complication of loss of differentiation. When tumor cells reduce the expression of NIS, thyroglobulin, thyroid peroxidase and other thyroid-specific genes, radioactive iodine treatment loses its effectiveness. This phenomenon is promoted by persistent MAPK activation, unfavorable co-mutations, dedifferentiation and clonal selection after treatment. Radioiodine-refractory disease does not always imply an immediately unfavorable prognosis because it may remain stable, but it becomes problematic when it is progressive or symptomatic. The true complication is the loss of a selective, minimally invasive treatment and the need for systemic therapies associated with chronic toxicity.
Surgical complications include transient or permanent hypoparathyroidism, hypocalcemia, recurrent laryngeal nerve injury, superior laryngeal nerve injury, compressive cervical hematoma, infection, seroma, pain, pathological scarring and lymphatic leakage after lateral neck dissection. Hypoparathyroidism causes paresthesia, cramps, tetany, QT prolongation and the need for calcium and calcitriol. Recurrent laryngeal nerve injury causes dysphonia and, when bilateral, may produce acute respiratory compromise. Prevention depends on surgical experience, anatomical identification, preservation of parathyroid vascularization, correct compartment-oriented dissection and appropriate selection of the extent of surgery. Surgical morbidity is the main reason for avoiding overtreatment in very low-risk tumors.
Radioactive iodine may cause radiation thyroiditis of the remnant, nausea, cervical pain, sialadenitis, xerostomia, altered taste, dental caries, obstruction of the salivary ducts, dry eyes, altered tearing, a transient reduction in male or female fertility and, with high cumulative doses, a small increase in the risk of second malignancies or bone marrow toxicity. These risks do not preclude the use of radioactive iodine when it is indicated, but they make its automatic use unacceptable in patients at very low risk. Radioactive iodine treatment must be justified by an expected benefit in terms of ablation, adjuvant treatment or treatment of radioiodine-avid disease.
Chronic TSH suppression may cause iatrogenic subclinical thyrotoxicosis, with palpitations, tachycardia, atrial fibrillation, loss of bone mass, an increased fracture risk in postmenopausal women and worsening of pre-existing heart disease. In patients who are cured or at low risk, maintaining intensive suppression for years may cause more harm than benefit. In patients with persistent disease, by contrast, suppression may form part of oncological control. The complication arises when treatment is not recalibrated according to the response to therapy.
There is also a diagnostic and psychological complication: overdiagnosis. The discovery of indolent microcarcinomas may transform a lesion that would never have caused symptoms into a sequence of surgery, hormone therapy, surveillance, anxiety and possible complications. This does not diminish the seriousness of aggressive papillary carcinoma, but it requires proportionate medical care. The clinical task is to identify invasive, metastatic or biologically unfavorable tumors promptly while avoiding treating minimal low-risk carcinomas as lethal diseases. The best prevention of complications is accurate risk stratification from the outset.